SCHEMBL25190965

SCHEMBL25190965

CC(C)(C)OC(=O)C1CCN(C(=O)[C@H]2CC[C@H](Oc3ccc(C4CCC(=O)NC4=O)cc3)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 9/20 0.48
▸ DDB1 Q16531 8/20 0.48
▸ POLB P06746 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ GPR119 Q8TDV5 2/20 0.39
▸ MAPT P10636 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25265235 1.00 CRBN (0.48) CRBNDDB1POLBL3MBTL1GPR119
SCHEMBL25188959 0.87 CRBN (0.48) CRBNDDB1POLBL3MBTL1MAPT
SCHEMBL25200407 0.87 CRBN (0.48) CRBNDDB1POLBL3MBTL1MAPT
SCHEMBL25205685 0.86 CRBN (0.51) CRBNDDB1POLBGPR119
SCHEMBL25502422 0.85 CRBN (0.50) CRBNDDB1POLBL3MBTL1MAPT
SCHEMBL30441494 0.85 CRBN (0.50) CRBNDDB1POLBL3MBTL1MAPT
SCHEMBL29223447 0.84 CRBN (0.62) CRBNDDB1POLBGPR119
SCHEMBL25191688 0.83 CRBN (0.46) CRBNDDB1POLBL3MBTL1MAPT
SCHEMBL25191709 0.83 CRBN (0.46) CRBNDDB1POLBL3MBTL1MAPT
SCHEMBL25193827 0.83 CRBN (0.51) CRBNDDB1POLBGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS INC (US) 2024-12-05 — — US disclosed
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof NURIX THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. 2024-01-18 — — US disclosed
WO-2023086399-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. (US) 2023-05-19 — — WO disclosed
WO-2023086399-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof TTK, HIPK1, CLK1 CRBN 218/4885DDB1 675/4885POLB 1715/4885
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 CRBN 218/4885DDB1 675/4885POLB 1715/4885
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 CRBN 218/4885DDB1 675/4885POLB 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback